Trials / Conditions / Stage I Marginal Zone Lymphoma

Stage I Marginal Zone Lymphoma

19 registered clinical trials studyying Stage I Marginal Zone Lymphoma.

Status	Trial	Sponsor	Phase
Completed	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphom NCT02213913	University of Chicago	Phase 1 / Phase 2
Completed	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477	Case Comprehensive Cancer Center	EARLY_Phase 1
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Terminated	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037	Northwestern University	Phase 1 / Phase 2
Completed	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256	Barbara Ann Karmanos Cancer Institute	N/A
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Terminated	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928	Case Comprehensive Cancer Center	Phase 1
Terminated	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745	University of Nebraska	Phase 2
Completed	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT00891072	National Cancer Institute (NCI)	Phase 1
Completed	Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, NCT01682044	Roswell Park Cancer Institute	Phase 2
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001	Fred Hutchinson Cancer Center	Phase 2
Completed	Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma NCT00244855	Fred Hutchinson Cancer Center	Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011	Fred Hutchinson Cancer Center	Phase 2
Completed	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Man NCT00058227	National Cancer Institute (NCI)	Phase 1
Completed	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846	Fred Hutchinson Cancer Center	Phase 2
Completed	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lympho NCT00017381	National Cancer Institute (NCI)	EARLY_Phase 1
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A